Severe neonatal morbidity index: RR 2.66 (95% CI, 1.69 to 4.18)
Severe perinatal morbidity and mortality index: RR 2.14 (95% CI, 1.66 to 2.75)
Fever and shortness of breath for any duration was associated with increased risk of
Severe maternal complications: RR 2.56 (95% CI, 1.92 to 3.40)
Neonatal complications: RR 4.97 (95% CI, 2.11 to 11.69)
Asymptomatic women with COVID-19 diagnosis were at higher risk for only a few complications
Maternal morbidity: RR 1.24 (95% CI, 1.00 to 1.54)
Preeclampsia: RR 1.63 (95% CI, 1.01 to 2.63)
Among women who tested positive by PCR testing
13% of their neonates tested positive
There was an increased risk of neonatal test positivity with cesarean delivery, but not with breastfeeding
Cesarean delivery: RR 2.15 (95% CI, 1.18 to 3.91)
Breastfeeding: RR 1.10 (95% CI, 0.66 to 1.85)
In a large-scale, prospective, matched, multinational study that included pregnant women from 18 countries, SARS-CoV-2 infection was associated with an increased risk of complications, including preeclampsia, mortality, preterm birth
Asymptomatic women were generally at similar risk levels to not-COVID-19 women except for preeclampsia
The authors state specifically regarding preeclampsia
…women with COVID-19 diagnosis, already at high risk of preeclampsia and COVID-19 because of preexisting overweight, diabetes, hypertension, and cardiac and chronic respiratory diseases,28 had almost 4 times greater risk of developing preeclampsia/eclampsia, which could reflect the known association with these comorbidities and/or the acute kidney damage that can occur in patients with COVID-19
Our data support reports of an association between COVID-19 and higher rates of preeclampsia/eclampsia/HELLP syndrome, but it is still uncertain whether COVID-19 manifests in pregnancy with a preeclampsialike syndrome or infection with SARS-CoV-2 results in an increased risk for preeclampsia
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan